Parabilis Medicines IPO Prices Above Range at $20, Raises $745M
Summary
Parabilis Medicines priced its upsized initial public offering at $20 per share, exceeding the expected range of $17 to $19. This successful pricing, which follows earlier reports of the upsized offering and its $20 price, indicates strong market demand. The company raised a total of $745 million, comprising $670 million from the IPO and an additional $75 million from a concurrent private placement with collaboration partner Regeneron Pharmaceuticals. This substantial capital infusion will significantly bolster the clinical-stage biopharmaceutical company's financial position. Shares are scheduled to begin trading today.
This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.